Search PubMed⌕ Search

Biomedical subjects

H Goldschmidt

Publications and source records attributed to H Goldschmidt.

184 records · Page 11Linked to original sources
PubMedDate not supplied

Ceftriaxone for the treatment of febrile episodes in nonneutropenic patients with hematooncological disease or HIV infection: comparison of outpatient and inpatient care.

BACKGROUND: Patients with hematooncological disease or HIV infection and febrile episodes are usually treated in hospital with broad-spectrum antibiotics. The aim of this observational study was to assess the feasibility of ambulatory parenteral antibiotic therapy in hematooncological or HIV-infected patients with confirmed or suspected infection. METHODS: The results in an outpatient treatment group were compared with those obtained in a group initially treated in hospital. Data were gathered on 90 outpatients and 72 inpatients. The inclusion criteria were fever > or =37.5 degrees C with an identified focus of infection, fever > or =38.0 degrees C of suspected bacterial origin with no identified focus of infection, leukocytosis > or =9,000/microl or C-reactive protein elevation > or =10 mg/l. RESULTS: Eighty outpatients and 69 inpatients were evaluable. Treatment in the outpatient group was begun with ceftriaxone. This led to defervescence in 87.5% of cases. The mean treatment duration was 7.1 days. Comparison of results in the outpatients with those initially hospitalized for treatment showed similar success rates. The mean hospital stay in the latter group was 12.9 days. CONCLUSIONS: Ceftriaxone represents an effective treatment for outpatient management of febrile episodes in patients with hematooncological disease or HIV infection. Outpatient treatment is more cost-effective than inpatient care.

Adolescent↗
PubMedDate not supplied

Detection of treated liver metastases using fluorine-18-fluordeoxyglucose (FDG) and positron emission tomography (PET).

The aim of the study was the evaluation of the detectability of treated liver metastases using one FDG-PET measurement. The study includes 42 patients (80 lesions) from different primary tumours. Standardized Uptake Values (SUV) as well as the tumour to liver Ratio (T/L) were used for evaluation. A T/L > 1.0 was considered to be pathological. Clinical follow-up data for at least 6 months were used as a reference. The median value of the FDG-uptake was 2.9 SUV in all liver metastases. The sensitivity based on a T/L ratio exceeding 1.0 was 82.5% (66/80 lesions). 25 of 80 (31%) lesions had a ratio T/L higher than 2.0 and were clearly visualized by PET. Negative results with a ratio T/L < 1.0 were raised in 14 of 80 treated metastatic lesions (17.5%). Although these metastases were hypometabolic, they were correctly classified due to the image correlation with computed tomography (CT) or magnetic resonance (MR) images or due to a baseline FDG-study prior to the onset of therapy. False positive results were not noted in this study. FDG-PET is a reliable method for the evaluation of treated liver metastases. A baseline FDG study prior to therapy is preferable for the interpretation.

Blood Glucose↗